Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement

Mayo Clin Proc. 2019 Nov;94(11):2361-2364. doi: 10.1016/j.mayocp.2019.09.006.

Authors

Mattia Novo¹, Michael W Ruff², Pamela J Skrabek³, Yi Lin⁴

Affiliations

¹ Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino, Torino, Piemonte, Italy; Mayo Clinic, Rochester, MN.
² Mayo Clinic, Rochester, MN.
³ University of Manitoba, Winnipeg, Manitoba, Canada; CancerCare Manitoba, Winnipeg, Manitoba, Canada.
⁴ Mayo Clinic College of Medicine, Rochester, MN.

PMID: 31685159
DOI: 10.1016/j.mayocp.2019.09.006

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antigens, CD19 / therapeutic use*
Biological Products
Central Nervous System Neoplasms / diagnosis*
Central Nervous System Neoplasms / drug therapy*
Humans
Immunotherapy, Adoptive
Lymphoma, Large B-Cell, Diffuse / diagnosis*
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Male
Middle Aged

Substances

Antigens, CD19
Biological Products
axicabtagene ciloleucel